FIG. 3.

In vivo DMS footprinting of the M-MuLV 5′ LTR in infected lymphoid cells. (A) In vivo DMS-LMPCR footprinting analogous to that described for Fig. 2 was carried out with M-MuLV-infected Ti-6 lymphoid cells. Infected Ti-6 cells were subjected to LMPCR after two independent in vivo DMS treatments. In this figure, the LMPCR fragments were visualized by PhosphorImaging. The same convention as that described for Fig. 2 was used, with arrows indicating protected and hypersensitive sites. (B) Digital densitometric analysis of the PhosphorImaged sequencing gel in panel A was performed. The positions of the NF-1, LVb/Ets, and Core sites are indicated. The portion of the Ti-6 gel analyzed is aligned above the graph.